CA3196153A1 - Pyrido[4,3-b]indole derivatives and their use as pharmaceuticals - Google Patents

Pyrido[4,3-b]indole derivatives and their use as pharmaceuticals

Info

Publication number
CA3196153A1
CA3196153A1 CA3196153A CA3196153A CA3196153A1 CA 3196153 A1 CA3196153 A1 CA 3196153A1 CA 3196153 A CA3196153 A CA 3196153A CA 3196153 A CA3196153 A CA 3196153A CA 3196153 A1 CA3196153 A1 CA 3196153A1
Authority
CA
Canada
Prior art keywords
compound
substituted
unsubstituted
disease
halogen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3196153A
Other languages
English (en)
French (fr)
Inventor
Lee Fader
Jason Burch
Miguel St-Onge
Stephane Dorich
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ventus Therapeutics US Inc
Original Assignee
Ventus Therapeutics US Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ventus Therapeutics US Inc filed Critical Ventus Therapeutics US Inc
Publication of CA3196153A1 publication Critical patent/CA3196153A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CA3196153A 2020-09-24 2021-09-23 Pyrido[4,3-b]indole derivatives and their use as pharmaceuticals Pending CA3196153A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063082695P 2020-09-24 2020-09-24
US63/082,695 2020-09-24
PCT/US2021/051670 WO2022066851A1 (en) 2020-09-24 2021-09-23 PYRIDO[4,3-b]INDOLE DERIVATIVES AND THEIR USE AS PHARMACEUTICALS

Publications (1)

Publication Number Publication Date
CA3196153A1 true CA3196153A1 (en) 2022-03-31

Family

ID=80846865

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3196153A Pending CA3196153A1 (en) 2020-09-24 2021-09-23 Pyrido[4,3-b]indole derivatives and their use as pharmaceuticals

Country Status (7)

Country Link
US (1) US20240018138A1 (https=)
EP (1) EP4216940A4 (https=)
JP (1) JP2023543254A (https=)
CN (1) CN116209442A (https=)
AU (1) AU2021349249A1 (https=)
CA (1) CA3196153A1 (https=)
WO (1) WO2022066851A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022137085A1 (en) 2020-12-22 2022-06-30 Novartis Ag Indole derivatives useful in treating conditions associated with cgas
EP4496796A1 (en) * 2022-03-22 2025-01-29 Ventus Therapeutics U.S., Inc. Hexahydropyrido[4,3-b]indolyl ketone derivatives useful as cgas modulators
AU2023409125A1 (en) * 2022-12-21 2025-06-26 Eli Lilly And Company Azepino[4,5-b]indolone cgas inhibitors
AU2024326748A1 (en) 2023-08-18 2026-04-02 Katholieke Universiteit Leuven 1,3-dihydro-2h-pyrrolo[3,4-c]quinoline derivatives as cgas inhibitors for the treatment of inflammatory and/or autoimmune diseases
CN119490508A (zh) * 2023-08-21 2025-02-21 上海交通大学 一类螺环四氢-γ-咔啉衍生物的制备方法以及应用
WO2025218659A1 (en) * 2024-04-16 2025-10-23 Insilico Medicine Ip Limited Novel compounds as cyclic gmp-amp synthase inhibitor and uses thereof
WO2026026969A1 (zh) * 2024-08-01 2026-02-05 杭州英创医药科技有限公司 作为cGAS抑制剂的化合物

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2424366B1 (en) * 2009-04-29 2016-02-17 Medivation Technologies, Inc. Pyrido [4, 3-b]indoles and methods of use
EP3472162B1 (en) * 2016-06-16 2021-11-17 F. Hoffmann-La Roche AG Heteroaryl estrogen receptor modulators and uses thereof
CN111511729A (zh) * 2017-12-19 2020-08-07 默克专利股份公司 Tlr7/8拮抗剂及其用途
BR112020016008A2 (pt) * 2018-02-05 2020-12-15 The Rockefeller University Composto, método para inibir uma resposta inflamatória em um paciente, método para inibir inflamação em um paciente, método para inibir expressão de interferon ativada por dsdna em um mamífero, método para tratar metástase de câncer em um paciente e formulação farmacêutica
CA3125625A1 (en) * 2019-01-04 2020-07-09 Bellbrook Labs, Llc Inhibitors of cgas activity as therapeutic agents
US12522603B2 (en) * 2019-03-13 2026-01-13 The Rockefeller University Inhibitors of gas for treating autoinflammatory diseases and cancer metastasis

Also Published As

Publication number Publication date
AU2021349249A1 (en) 2023-04-13
JP2023543254A (ja) 2023-10-13
EP4216940A1 (en) 2023-08-02
EP4216940A4 (en) 2025-01-01
WO2022066851A1 (en) 2022-03-31
CN116209442A (zh) 2023-06-02
US20240018138A1 (en) 2024-01-18

Similar Documents

Publication Publication Date Title
CA3196153A1 (en) Pyrido[4,3-b]indole derivatives and their use as pharmaceuticals
CN113286794B (zh) Kras突变蛋白抑制剂
CN112638380B (zh) 小脑蛋白(crbn)配体
CN116390923B (zh) 杂环类衍生物及其制备方法和用途
JP7711073B2 (ja) 免疫抑制剤として有用な大環状ｐａｄ４阻害剤
JP2021535909A (ja) 高活性ｓｔｉｎｇタンパク質アゴニスト化合物
EP3917926B1 (en) Imidazoquinoline amine derivatives, pharmaceutical composition, use thereof
KR101272263B1 (ko) 감염 방지제로서 사용되는8-메톡시-9ｈ-이소티아졸로［5,4-ｂ］퀴놀린-3,4-디온 및관련 화합물
AU2012293618B2 (en) Antibacterial homopiperidinyl substituted 3,4 dihydro 1H (1,8)naphthyridinones
CN114641472A (zh) 用于治疗疾病的双亮氨酸拉链(dlk)激酶的双环[1.1.1]戊烷抑制剂
US11858938B2 (en) Imidazo-fused heterocycles and uses thereof
CN119173505A (zh) 抗病毒杂环化合物
AU2023254925A1 (en) Imidazo[1,5-a]pyrazine derivatives as PI3Kdelta inhibitors
JP2018531993A (ja) Ａｌｋおよびｓｒｐｋ阻害剤ならびに使用方法
RS55201B1 (sr) Antimalarijski agensi
CA3087926A1 (en) Cycloalkyl substituted pyrazolopyrimidines having activity against rsv
WO2016196910A1 (en) Compounds for the modulation of myc activity
KR20240121746A (ko) 테트라하이드로피리다진, 이를 포함하는 조성물, 및 이의 용도
WO2023143249A1 (zh) 靶向malt1的蛋白降解化合物
WO2021233394A1 (en) Receptor-interacting protein 1 inhibitors including piperazine heterocyclic amide ureas
US20240132464A1 (en) Heterocyclic compounds as e3 ligase inhibitors
HK40093069A (zh) 吡啶并[4，3-b]吲哚衍生物及其作为药物的用途
KR20260025059A (ko) 신규한 치환된 피리딘 유도체 화합물, 이의 제조방법, 및 이를 유효성분으로 포함하는 호흡기 질환의 예방 또는 치료용 약학적 조성물
US20210221820A1 (en) Compounds for the modulation of myc activity
WO2024207131A1 (en) Ferroptosis inhibitors–phenoxazine acetamides

Legal Events

Date Code Title Description
MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD

Year of fee payment: 3

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20240826

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20240826

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20240826

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20251106

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260310